Kennedy Ferruggia, Assistant Editor

New research highlights the significant health risks of respiratory syncytial virus (RSV) in older adults, emphasizing the need for effective vaccines and public health strategies.

Combining omega-3 supplements with exercise enhances immune response and alleviates tooth infections, offering new insights into managing apical periodontitis.

New research reveals a significant link between type 2 diabetes, obesity, and fatty liver disease.

The FDA approves garadacimab-gxii, a treatment for hereditary angioedema (HAE), offering convenient monthly self-injections for patients 12 years and older.

Eli Lilly is expanding access to tirzepatide, a groundbreaking GLP-1 medication for weight management, offering more affordable options for obesity treatment.

Discover the latest FDA-approved treatments, including Dupixent for chronic urticaria and Valtoco for seizure clusters, enhancing patient care options.

Nemolizumab shows promising long-term efficacy in reducing itch and skin lesions for atopic dermatitis, enhancing quality of life for patients.

Moderna's mRNA-1345 vaccine gains FDA approval, enhancing protection against RSV for high-risk adults aged 18 to 59 years, following earlier approvals for older populations.

Ribociclib plus endocrine therapy shows improved survival in HR+, HER2- breast cancer, but its cost-effectiveness raises concerns in the US market.

Vitamin D could offer an alternative option over hard-to-access and burdensome cancer drugs to heighten the response of chemotherapy.

New research reveals how individual blood glucose responses to carbohydrates vary, highlighting the importance of personalized dietary approaches for diabetes management.

Pharmacists play a critical role in managing complex pericarditis cases.

The expansion marks glecaprevir/pibrentasvir as the first and only indicated direct-acting antiviral approved for acute hepatitis C virus (HCV) infection.

Combining GLP-1 therapy with specific antibodies can reduce muscle loss during weight management, enhancing overall health outcomes.

The FDA approves clesrovimab-cfor, a new RSV vaccine, offering infants effective protection against severe respiratory illness during their first RSV season.

Nivolumab plus relatlimab does not significantly improve recurrence-free survival in patients with stage 3, 4 melanoma.

A new study reveals the combination therapy enhances safety and efficacy for high-risk BRAF-mutated stage II melanoma.

Rilonacept offers a targeted approach to treating recurrent pericarditis by blocking IL-1 inflammatory pathways.

New research analyzes human challenge infection studies to reveal insights on respiratory syncytial virus viral load and symptom dynamics, aiding treatment development.

Patients with diabetes using glucagon-like peptide-1 (GLP-1) drugs face double the risk of developing neovascular age-related macular degeneration, highlighting crucial ocular health concerns.

Pharmacists navigate reimbursement challenges while advocating for legislative support and innovative models to enhance patient care and financial sustainability.

New research highlights vitamin D's potential to slow telomere shortening, suggesting it may combat aging and promote cellular health.

Although women might benefit from fattier breakfasts, men could respond best to carbohydrates.

New findings show LYR-210's potential to significantly alleviate chronic rhinosinusitis symptoms, offering hope for patients with nasal inflammation and polyps.

Clairity Breast's FDA-approved AI platform revolutionizes breast cancer risk prediction, enhancing early detection and personalized prevention strategies.

Electronic prior authorization (EPA) technology can streamline the complex process of obtaining prior authorizations for GLP-1 medications.

Zongertinib shows promising efficacy and safety for HER2-mutant NSCLC, with a 71% response rate and low toxicity, paving the way for future treatments.

The FDA designated Hadlima as an interchangeable biosimilar to Humira, enhancing patient access and potential savings for various conditions.

A study of early-onset colorectal cancer found significant racial disparities, with younger patients more frequently diagnosed at advanced stages.

The FDA grants fast track designation to TEV-53408, a promising treatment for celiac disease designed to address gluten intolerance and improve patient outcomes.